Dr Nicholas Silvestri reports that the 2025 AAN meeting highlighted significant advances in myasthenia gravis, including ...

Innovative Medicine: nipocalimab in gMG; RYBREVANT Sub-Q in NSCLC; TREMFYA Sub-Q in UC; TAR-200 NMIBC; icotrokinra in PsO and UC; RYBREVANT in ...

Researchers at AAN meeting discuss myasthenia gravis advances as J&J reports long-term data for nipocalimab, while argenx's ...

Johnson & Johnson announced compelling results from its Phase 3 Vivacity-MG3 study on nipocalimab, showing promising efficacy and safety in treating generalized myasthenia gravis, which were ...

After dropping the FNAIT therapy, Rallybio will prioritise another candidate that is being investigated in complement-driven ...

Learn about the treatments currently available for HDFN as well as the only therapy in development for this rare disease.

Johnson & Johnson (NYSE:JNJ) on Tuesday announced results from additional analyses of the Phase 3 Vivacity-MG3 study and the ...

J&J exhibited additional findings from the Vivacity-MG3 study, displaying that nipocalimab met its key secondary endpoint.

If the FDA approves nipocalimab, the long-term data could form part of J&J’s pitch for the gMG market. The labels for ...

Johnson & Johnson announced results from additional analyses of the Phase 3 Vivacity-MG3 double-blind study and the ongoing open-label ...

LOG Pharma Primary Packaging, a leading global provider of innovative packaging solutions for the pharmaceutical industry, offers drug manufacturers a complete, integrated packaging solution. By ...

The summary describes the design of Johnson & Johnson's Phase 3 AZALEA trial, which will evaluate the efficacy of nipocalimab in HDFN.